Boston-based Antidote Technologies expects it will soon be able to accelerate the development of capabilities for its trial matching platform – including precision medicine and EHR matching. That’s because the company has just entered into an agreement for an $11 million funding round led by Merck Global Health Innovation Fund, and joined by existing investors Smedvig Capital and Octopus Ventures...
